The vaccine is based on a protein called Nuvaxovid and has become the fifth COVID-19 vaccine to be
approved in the country, following the vaccines of British-Swedish pharmaceutical giant AstraZeneca
and Oxford University, Pfizer Inc., Johnson & Johnson and Moderna Inc. The vaccine can be given to
people aged 18 years and older and the second injection will be given 21 days after the first. A study
conducted in Britain showed a reduction in the number of symptomatic cases of COVID-19 with a
vaccine effectiveness of 89.7 per cent.
Performance of Novavax Inc. (Source: Investing.com)